Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MANNKIND CORPMNKD · Entity 4792 | Director · Chief Executive Officer | July 15, 2026 | July 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MANNKIND CORP
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 2,796,979 |
Reported balance
After 2026-07-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-15 · Exercise / conversion · Acquired 350,260 · Balance 2,796,979 F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. F2: Includes 4,409 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 2,604,160 |
Reported balance
After 2026-07-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-15 · Tax withholding · Disposed 192,819 · Balance 2,604,160 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 2,556,679 |
Reported balance
After 2026-07-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-07-15 · Tax withholding · Disposed 47,481 · Balance 2,556,679 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 2,492,683 |
Reported balance
After 2026-07-15 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-07-15 · Tax withholding · Disposed 63,996 · Balance 2,492,683 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 2,433,779 |
Reported balance
After 2026-07-15 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-07-15 · Tax withholding · Disposed 58,904 · Balance 2,433,779 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Performance Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Exercise / conversion · Disposed 350,260 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria.
F2: Includes 4,409 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.
F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
F4: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 18, 2026 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionPerformance Restricted Stock Unit · Derivative | 350,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-308133 · ownership.xml · derivative · entry 6 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.01 Par Value · 350,260 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. F1 · derivative.exercise_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. F1 · derivative.expiration_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. F1 · balance_after: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 58,904 | $4.09 | $240,917.36 |
DisclosureSEC source: 0001193125-26-308133 · ownership.xml · nonDerivative · entry 5 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,433,779 F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 63,996 | $4.09 | $261,743.64 |
DisclosureSEC source: 0001193125-26-308133 · ownership.xml · nonDerivative · entry 4 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,492,683 F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 47,481 | $4.09 | $194,197.29 |
DisclosureSEC source: 0001193125-26-308133 · ownership.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,556,679 F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 192,819 | $4.09 | $788,629.71 |
DisclosureSEC source: 0001193125-26-308133 · ownership.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,604,160 F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionCommon Stock, $0.01 Par Value | 350,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-308133 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,796,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. F2 · balance_after: Includes 4,409 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. Read SEC document |
| May 11, 2026 Filed May 14, 2026 00:30 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 34,957 | $3.52 | $123,048.64 |
DisclosureSEC source: 0001193125-26-222309 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,442,310 F1 · shares: Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 10, 2022. F2 · balance_after: Includes 1,356 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2025. Read SEC document |
| March 23, 2026 Filed Mar 26, 2026 01:30 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 782,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001193125-26-124725 · ownership.xml · derivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 782,000 Underlying: Common Stock, $0.01 Par Value · 782,000 shares Expires 2036-03-23 F3 · derivative.exercise_date: 25% vesting on March 23, 2027 and thereafter 1/16th quarterly. Read SEC document |
| March 23, 2026 Filed Mar 26, 2026 01:30 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 796,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-124725 · ownership.xml · derivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 796,000 Underlying: Common Stock, $0.01 Par Value · 796,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F2 · derivative.expiration_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 01:30 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 100,000 | $2.59 | $259,000.00 |
DisclosureSEC source: 0001193125-26-100839 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,575,911 F1 · price: The weighted average purchase price of the reported transaction was $2.59 based on a range of prices between $2.58 and $2.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 02:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 15,290 | $3.27 | $49,998.30 |
DisclosureSEC source: 0001193125-26-086379 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,475,911 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on March 1, 2026. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 02:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 37,525 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001193125-26-086379 · ownership.xml · derivative · entry 4 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,525 Underlying: Stock Options · 37,525 shares Expires 2027-05-25 F4 · kind: On May 25, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 02:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 57,750 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001193125-26-086379 · ownership.xml · derivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,750 Underlying: Stock Options · 57,750 shares Expires 2027-05-29 F3 · kind: On May 29, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 02:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001193125-26-086379 · ownership.xml · derivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Stock Options · 50,000 shares Expires 2026-05-19 F2 · kind: On May 19, 2016, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option. Read SEC document |
| December 24, 2025 Filed Dec 30, 2025 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GiftCommon Stock, $0.01 Par Value | 44,171 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-335655 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,460,621 F1 · kind: Shares gifted as a charitable donation. Read SEC document |
| December 17, 2025 Filed Dec 20, 2025 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001193125-25-327227 · ownership.xml · derivative · entry 4 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.01 Par Value · 50,000 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2025 Filed Dec 20, 2025 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,804 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001193125-25-327227 · ownership.xml · derivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.01 Par Value · 15,804 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2025 Filed Dec 20, 2025 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 65,804 | $6.01 | $395,482.04 |
DisclosureSEC source: 0001193125-25-327227 · ownership.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,504,792 F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 8, 2025. F2 · price: The weighted average sales price of the reported transaction was $6.01 based on a range of prices between $6.00 and $6.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 17, 2025 Filed Dec 20, 2025 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionCommon Stock, $0.01 Par Value | 65,804 | $4.55 | $299,408.20 |
DisclosureSEC source: 0001193125-25-327227 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,570,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 01:15 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,310 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001193125-25-321366 · ownership.xml · derivative · entry 7 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,804 Underlying: Common Stock, $0.01 Par Value · 21,310 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 01:15 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 21,310 | $6.00 | $127,860.00 |
DisclosureSEC source: 0001193125-25-321366 · ownership.xml · nonDerivative · entry 4 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,504,792 F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 8, 2025. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 01:15 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionCommon Stock, $0.01 Par Value | 21,310 | $4.55 | $96,960.50 |
DisclosureSEC source: 0001193125-25-321366 · ownership.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,526,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 01:15 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,886 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001193125-25-321366 · ownership.xml · derivative · entry 6 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,114 Underlying: Common Stock, $0.01 Par Value · 12,886 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 01:15 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,920 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001193125-25-321366 · ownership.xml · derivative · entry 5 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.01 Par Value · 7,920 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 01:15 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 20,806 | $6.00 | $124,836.00 |
DisclosureSEC source: 0001193125-25-321366 · ownership.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,504,792 F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 8, 2025. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 01:15 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionCommon Stock, $0.01 Par Value | 20,806 | $4.55 | $94,667.30 |
DisclosureSEC source: 0001193125-25-321366 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,525,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:32 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 42,080 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001193125-25-308350 · ownership.xml · derivative · entry 4 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,920 Underlying: Common Stock, $0.01 Par Value · 42,080 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:32 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 65,840 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001193125-25-308350 · ownership.xml · derivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.01 Par Value · 65,840 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:32 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 107,920 | $5.57 | $601,114.40 |
DisclosureSEC source: 0001193125-25-308350 · ownership.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,504,792 F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 8, 2025. F2 · price: The weighted average sales price of the reported transaction was $5.57 based on a range of prices between $5.50 and $5.63. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:32 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionCommon Stock, $0.01 Par Value | 107,920 | $4.55 | $491,036.00 |
DisclosureSEC source: 0001193125-25-308350 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,612,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2025 Filed Jul 18, 2025 00:47 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 111,275 | $3.85 | $428,408.75 |
DisclosureSEC source: 0000950170-25-096740 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,504,792 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. F2 · balance_after: Includes 3,133 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025. Read SEC document |
| May 19, 2025 Filed May 21, 2025 01:46 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 26,114 | $4.37 | $114,118.18 |
DisclosureSEC source: 0000950170-25-075538 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,612,934 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 14, 2025 Filed May 16, 2025 22:20 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 27,000 | $4.56 | $123,120.00 |
DisclosureSEC source: 0000950170-25-073801 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,639,048 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on May 14, 2025. Read SEC document |
| May 13, 2025 Filed May 16, 2025 01:29 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 523,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073078 · ownership.xml · derivative · entry 5 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,000 Underlying: Common Stock, $0.01 Par Value · 523,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F5 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F5 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 13, 2025 Filed May 16, 2025 01:29 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 428,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073078 · ownership.xml · nonDerivative · entry 4 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,612,048 F3 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. Read SEC document |
| May 12, 2025 Filed May 16, 2025 01:29 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 34,894 | $4.56 | $159,116.64 |
DisclosureSEC source: 0000950170-25-073078 · ownership.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,184,048 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 12, 2025 Filed May 16, 2025 01:29 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 334,954 | $4.56 | $1,527,390.24 |
DisclosureSEC source: 0000950170-25-073078 · ownership.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,218,942 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2025 Filed May 16, 2025 01:29 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 298,560 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073078 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,553,896 F1 · kind: A previously reported restricted stock unit award granted on May 10, 2022 vested on May 10, 2025 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 9, 2025 was not less than the closing price on May 10, 2022 and (ii) MannKind's total shareholder return (TSR) over the period from May 10, 2022 to May 10, 2025 was at the 73.9th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 196% of target, resulting in a total share delivery of 609,560 shares. The acquisition of 311,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 12, 2022. Read SEC document |
| April 04, 2025 Filed Apr 5, 2025 00:54 UTC | MANNKIND CORP MNKD · Entity 4792 | OtherCommon Stock, $0.01 Par Value | 39,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-051315 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,255,336 F1 · kind: Reporting person transferred 39,500 shares of MNKD common stock to his ex-spouse pursuant to a divorce decree. Read SEC document |
| August 29, 2024 Filed Aug 30, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 85,106 | $6.30 | $536,167.80 |
DisclosureSEC source: 0000950170-24-102043 · ownership.xml · nonDerivative · entry 4 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,294,836 Read SEC document |
| August 29, 2024 Filed Aug 30, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GiftCommon Stock, $0.01 Par Value | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-102043 · ownership.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,379,942 F2 · kind: Shares gifted as a charitable donation. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GiftCommon Stock, $0.01 Par Value | 13,894 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-102043 · ownership.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,398,942 F2 · kind: Shares gifted as a charitable donation. Read SEC document |
| August 27, 2024 Filed Aug 30, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 56,085 | $5.38 | $301,737.30 |
DisclosureSEC source: 0000950170-24-102043 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,412,836 F1 · kind: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 23:49 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 47,309 | $5.83 | $275,811.47 |
DisclosureSEC source: 0000950170-24-084404 · ownership.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,468,921 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| June 30, 2024 Filed Jul 17, 2024 23:49 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 5,000 | $3.09 | $15,450.00 |
DisclosureSEC source: 0000950170-24-084404 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,516,230 F1 · kind: Shares acquired through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 18, 2024 Filed May 22, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 26,067 | $4.59 | $119,647.53 |
DisclosureSEC source: 0000950170-24-063261 · ownership.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,511,230 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 17, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | OtherCommon Stock, $.01 Par Value | 24,330 | $4.79 | $116,540.70 |
DisclosureSEC source: 0000950170-24-062071 · ownership.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,561,260 F4 · kind: Reporting person transferred 24,330 shares of MNKD common stock to his ex-spouse pursuant to a divorce decree. Read SEC document |
| May 17, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | OtherCommon Stock, $.01 Par Value | 28,670 | $4.32 | $123,854.40 |
DisclosureSEC source: 0000950170-24-062071 · ownership.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,585,590 F3 · kind: Reporting person transferred 28,670 shares of MNKD common stock to his ex-spouse pursuant to a divorce decree. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 245,443 | $4.59 | $1,126,583.37 |
DisclosureSEC source: 0000950170-24-063261 · ownership.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,537,297 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 221,480 | $4.59 | $1,016,593.20 |
DisclosureSEC source: 0000950170-24-063261 · ownership.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,782,740 F1 · kind: A previously reported restricted stock unit award granted on May 18, 2021 vested on May 17, 2024 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 17, 2024 was not less than the closing price on May 17, 2021 and (ii) MannKind's total shareholder return (TSR) over the period from May 18, 2021 to May 17, 2024 was at the 74.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 198% of target, resulting in a total share delivery of 447,480 shares. The acquisition of 226,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 18, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.